123 related articles for article (PubMed ID: 31740232)
41. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.
Schmidt KM; Dietrich P; Hackl C; Guenzle J; Bronsert P; Wagner C; Fichtner-Feigl S; Schlitt HJ; Geissler EK; Hellerbrand C; Lang SA
Neoplasia; 2018 Dec; 20(12):1198-1208. PubMed ID: 30404068
[TBL] [Abstract][Full Text] [Related]
43. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
Lee HE; Park KU; Yoo SB; Nam SK; Park DJ; Kim HH; Lee HS
Eur J Cancer; 2013 Apr; 49(6):1448-57. PubMed ID: 23146959
[TBL] [Abstract][Full Text] [Related]
44. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.
Barros-Silva JD; Leitão D; Afonso L; Vieira J; Dinis-Ribeiro M; Fragoso M; Bento MJ; Santos L; Ferreira P; Rêgo S; Brandão C; Carneiro F; Lopes C; Schmitt F; Teixeira MR
Br J Cancer; 2009 Feb; 100(3):487-93. PubMed ID: 19156142
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
[TBL] [Abstract][Full Text] [Related]
46. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
47. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.
Ooi A; Kobayashi M; Mai M; Nakanishi I
Lab Invest; 1998 Mar; 78(3):345-51. PubMed ID: 9520947
[TBL] [Abstract][Full Text] [Related]
48. The role of RICTOR amplification in targeted therapy and drug resistance.
Zhao D; Jiang M; Zhang X; Hou H
Mol Med; 2020 Feb; 26(1):20. PubMed ID: 32041519
[TBL] [Abstract][Full Text] [Related]
49. HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.
Liu X; Wang X; Wang B; Ren G; Ding W
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):459-64. PubMed ID: 26317310
[TBL] [Abstract][Full Text] [Related]
50. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
51. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
Barrett C; Magee H; O'Toole D; Daly S; Jeffers M
J Clin Pathol; 2007 Jun; 60(6):690-3. PubMed ID: 16822876
[TBL] [Abstract][Full Text] [Related]
52. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
Bhargava R; Lal P; Chen B
Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of Rictor protein and Rictor-H. pylori interaction has impact on tumor progression and prognosis in patients with gastric cancer.
Wang F; Lou X; Zou Y; Hu D; Liu J; Ning J; Jiao Y; Zhang Z; Yang F; Fan L; Yu H; Wei W; Wang H; Sun G
Folia Histochem Cytobiol; 2020; 58(2):96-107. PubMed ID: 32588907
[TBL] [Abstract][Full Text] [Related]
54. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
55. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Wixom CR; Albers EA; Weidner N
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
[TBL] [Abstract][Full Text] [Related]
56. [Clinical significance of HER2 positivity in gallbladder adenocarcinoma].
Yao JG; Wang CH; Liu Y
Zhonghua Bing Li Xue Za Zhi; 2017 Apr; 46(4):245-248. PubMed ID: 28376590
[No Abstract] [Full Text] [Related]
57. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
Marx AH; Burandt EC; Choschzick M; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Atanackovic D; Bokemeyer C; Fiedler W; Terracciano L; Sauter G; Izbicki JR
Hum Pathol; 2010 Nov; 41(11):1577-85. PubMed ID: 20656317
[TBL] [Abstract][Full Text] [Related]
58. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
[TBL] [Abstract][Full Text] [Related]
60. Amplification of the c-erbB-2 gene detected by FISH in gastric cancers.
Sato T; Abe K; Kurose A; Uesugi N; Todoroki T; Sasaki K
Pathol Int; 1997; 47(2-3):179-82. PubMed ID: 9088037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
